Citius Pharmaceuticals, Inc.

The Citius team had a productive FDA Type C meeting last week to discuss our Phase 3 Mino-Lok® program and the pathway to approval. Read the press release here: https://lnkd.in/eeXFxWhX

LYMPHIR™ (denileukin diftitox-cxdl or E7777) Combo Shows Promising ORR and CBR in Solid Tumors. A combined regimen of pembrolizumab (Keytruda) and denileukin diftitox-cxdl (E7777; Lymphir) yielded promising preliminary results in a small cohort of patients with recurrent or advanced metastatic solid tumors, early findings from a phase 1 study (NCT05200559) showed. Thank you Cancer Network for covering our news! Read more here: https://lnkd.in/eTQ488a4 #Biopharma

🎙️ New Podcast: Let’s Talk Rare Looking for an exciting podcast? Georgie Rack and Owen Bryant chat with Leonard Mazur CEO of Citius Pharmaceuticals, Inc. about the resubmission of #Lymphir for cutaneous T-cell lymphoma (#CTCL). Listen now via the links below. #LetsTalkRare #P4AInsights #RareDisease #CTCL #Lymphir #FDAApprovals #Biotech #Innovation

Pembrolizumab (Keytruda) Plus LYMPHIR™ (Denileukin Diftitox) Shows Promise in Solid Tumors. Thank you, Jordyn Sava for covering our news. Read via Targeted Oncology here: https://lnkd.in/ewtXnwYF #Biopharma

Safety is paramount so we’re thrilled that UPMC’s Phase I trial of a combination regimen of pembrolizumab (KEYTRUDA®) and denileukin diftitox-cxdl (LYMPHIR™) has been well-tolerated, with no significant immune-related adverse events reported. This positive result may allow patients to stay on treatment longer. https://bit.ly/48IHCDM #CancerResearch #PatientSafety #Immunotherapy

In case you missed our latest press release, read more here: https://bit.ly/48IHCDM #CancerResearch #MedicalResearch #ClinicalTrials #LYMPHIR #WomensHealth

Interim results from the Phase I pembrolizumab (KEYTRUDA®) + denileukin diftitox-cxdl (LYMPHIR™) combo trial conducted by the University of Pittsburgh show that out of the 15 evaluable patients, 4 achieved a partial response, and 1 demonstrated durable stable disease of more than six months. With median Progression Free Survival (PFS) of 57 weeks, we believe these early results hint at the future potential of this novel chemotherapy-free immunomodulatory combination regimen and merit further research in a Phase 2 study. In case you missed the press release, read more here: https://bit.ly/48IHCDM #CancerResearch #MedicalResearch #ClinicalTrials #LYMPHIR #WomensHealth #CitiusOncology #CitiusPharma

We’re excited to share promising interim results from a Phase I trial conducted by the University of Pittsburgh, evaluating pembrolizumab (KEYTRUDA®) and deniluekin diftitox-cxdl (LYMPHIR™) in cancer patients with recurrent solid tumors. This study, focusing on gynecological cancers, has demonstrated an encouraging objective response rate of 27% and a clinical benefit rate of 33%. Stay tuned as we share more insights this week! #Immunotherapy #OncologyResearch #ClinicalTrials #LYMPHIR https://lnkd.in/eHvTUJR8

Thank you Morey Stettner for featuring our CEO Leonard Mazur in your recent article ‘Find The Right Partners To Help You Attain Your Business Goals.’ Read more of his and other insights via Investor's Business Daily here: https://lnkd.in/eJWqkQUD 

“The inclusion of LYMPHIR in the NCCN Guidelines is a testament to the clinical evidence supporting this therapy and further supports #healthcare professionals in considering LYMPHIR as part of the recommended treatment protocols for #CTCL. We are grateful to the NCCN board for its recognition of LYMPHIR, paving the way for expanded access to this important treatment option. NCCN guidelines are widely regarded as the gold standard for clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S. We believe that LYMPHIR has the potential to improve CTCL patient outcomes, and expect its addition to the NCCN Guidelines may aid adoption and ease reimbursement, particularly for the anticipated patients that qualify for CMS coverage,” commented Leonard Mazur, CEO of Citius Pharma and Citius Oncology. #ICYMI, read the press release here: https://lnkd.in/eXKvwCQP #Oncology #Biotech